Randomized studies have demonstrated improved outcomes over SOC with addition of midostaurin to patients with FLT3 mutant AML [2], gemtuzumab ozogamicin (GO) for de novo CD33 + AML [3, 4], venetoclax for patients ineligible for intensive chemotherapy [5, 6], ivosidenib for elderly, unfit patients with IDH1 mutated AML [7], CPX-351 for patients with secondary/therapy-related AML [8] and oral azacitidine as maintenance therapy for patients ineligible for allogeneic hematopoietic cell transplantation (HCT) (Table 1) [9]. Here, IDH1 is linked to acute myeloid leukemia.